Accelerate to discover
Related topics
Next-generation cytogenetics is here
Aug 9, 2019
On ESHG 2019 conference several oral and poster presentations compared Bionano optical mapping to clinical cytogenetics...
Learning hub: Online video training for Vevo users
Jul 15, 2019
FUJIFILM VisualSonics Learning Hub! This new online learning portal is now available exclusively for our Vevo users and...
Assessment of angiotensin II-induced mouse models of abdominal aortic aneurysm
Jun 28, 2019
Are you working with high ultrasound imaging and are you interesting in progression/ regression of abdominal aortic...
Bionano introduce new SP blood and cell culture DNA isolation kit
Jun 26, 2019
This Bionano prep SP blood and cell culture DNA isolation kit, can provide ultra-high molecular weight (UHMW) gDNA in...
IncuCyte webinar: high throughput approach to developing T- Cell immunotherapies
Jun 17, 2019
Immunotherapy for cancers involves artificially prompting the immune system to treat cancer. Many cancer cells have...
Fluxion Biosciences and National Cancer Institute cooperate to validate IsoFlux for sequencing
Jun 12, 2019
Fluxion with IsoFlux has partnered with the Cleveland Clinic. They are aiming to improve sensitivity by timing the...
IncuCyte virtual event: Dimension of time - from culture to assay
Jun 5, 2019
This event offers an overview of how live-cell analysis enables real-time analysis for the full workflow of the cells....
Assessment of myocardial dynamics using photoacoustics & cardiac elastography
May 17, 2019
Are you interested in Principles of Photoacoustic (PA) Imaging, and its application in cardiovascular research? Don’t...
Nov 22, 2018
Researchers developed an assay to measure CLL cell interactions with endothelium under shear force using a Bioflux 200 and blocked CD62L using the anti-CD62L antibody DREG-56. CLL cell interactions with endothelium were visualized by time-lapse microscopy and CLL cell movement was tracked and quantified. Data will be discussed in the webinar and will establish targeting CD62L inhibits CLL cell/endothelial cell interactions and is accentuated by co-administration with ibrutinib. These data imply that some of the clinical effects caused by ibrutinib are due to a reduced capacity of CLL cells to engage endothelium and extravasate.
Dr. Chris Pepper, Professor in Cancer Studies, University of Sussex, UK
Related technologies: Cell interaction studies
Get more info
Brand profile
With BioFlux System for live cell analysis under shear flow and IsoFlux System for circulating tumor cell analysis, Fluxion Biosciences turn power of benchtop cellular analysis with advanced tools to automate complex assays.
More info at:
www.fluxionbio.com
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
